Predicting purification process fit of monoclonal antibodies using machine learning.

Journal: mAbs
PMID:

Abstract

In early-stage development of therapeutic monoclonal antibodies, assessment of the viability and ease of their purification typically requires extensive experimentation. However, the work required for upstream protein expression and downstream purification development often conflicts with timeline pressures and material constraints, limiting the number of molecules and process conditions that can reasonably be assessed. Recently, high-throughput batch-binding screen data along with improved molecular descriptors have enabled development of robust quantitative structure-property relationship (QSPR) models that predict monoclonal antibody chromatographic binding behavior from the amino acid sequence. Here, we describe a QSPR strategy for monoclonal antibody purification process fit assessment. Principal Component Analysis is applied to extract a one-dimensional basis for comparison of molecular chromatographic binding behavior from multi-dimensional high-throughput batch-binding screen data. Kernel Ridge Regression is used to predict the first principal component for new molecular sequences. This workflow is demonstrated with a set of 97 monoclonal antibodies for five chromatography resins in two salt types across a range of pH and salt concentrations. Model development benchmarks four descriptor sets from biophysical structural models and protein language models. The investigation illustrates the value QSPR models can provide to purification process fit assessment, and selection of resins and operating conditions from sequence alone.

Authors

  • Andrew Maier
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Minjeong Cha
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Sean Burgess
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Amy Wang
    From the Departments of Diagnostic Imaging (M.T.S., M.J., J.L.B., G.L.B., R.A.M.), Diagnostic Imaging (A.D.Y.), and Neurosurgery (M.J., R.A.M.), Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, 593 Eddy St, APC 701, Providence, RI 02903; Department of Computer Science, Brown University, Providence, RI (J.V., M.P.D., Y.H.K., S.S.S., H.J.T., A.W., H.L.C.W., C.E., U.C.); and the Norman Prince Neuroscience Institute, Rhode Island Hospital, Providence, RI (M.J., R.A.M.).
  • Carlos Cuellar
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Soo Kim
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Neeraja Sundar Rajan
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Josephine Neyyan
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Rituparna Sengupta
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Kelly O'Connor
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Nicole Ott
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
  • Ambrose Williams
    Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.